HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development Second Edition September 2011 Written by Polly Clayden, Simon Collins, Mark Harrington, Richard Jefferys, Tracy Swan, Javid Syed, and Claire Wingfield with a a contribution…
July 2011 - Investments in health research at the National Institutes of Health (NIH) have paid enormous dividends in the health and well-being of people in the U.S. and around the world. HIV and AIDS research supported by NIH has…
July 2011 - In 2010, the number of people receiving ART grew by 1.3 million from 5.3 to 6.6 million. Yet, 2.6 million new infections and 1.8 million AIDS deaths occurred. New infections continue to outpace the number of people…
Data collected for the first time on global investments in HIV treatment-related research and development showed that at least US$ 2.46 billion was available in 2009. The Treatment Action Group, AVAC, and the Joint United Nations Programme on HIV/AIDS (UNAIDS) issued the report which was released at the International AIDS Society's 6th Conference on HIV Pathogenesis, Prevention, and Treatment in Rome, Italy.
The new drug, diagnostic, and vaccine pipeline has never looked more promising for people with HIV, hepatitis C virus (HCV), and tuberculosis (TB), according to a report released today by Treatment Action Group (TAG) and HIV i-Base.
TAG Statement on the U.N. High Level Meetings on HIV/AIDS Outcome Document.
February 7, 2011 Dear Secretary Clinton, We write to ask for your leadership in ensuring The Global Fund to Fight AIDS, TB, and Malaria is “open for new business,” saving lives through expanding programming in 2012. We ask that you…
Treatment Action Group outlines issues of concern and questions about network restructuring research priorities and network structure. Jan 4, 2011 - Treatment Action Group (www.treatmentactiongroup.org) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine,…
The many complications and comorbidities faced by the aging population of HIV positive people in the United States constitute a rapidly growing medical crisis that has been woefully neglected by U.S. research efforts.